SAN JOSE, Calif., April 22, 2026 – BrightInsight, the patient persistence solution for the world's top pharma and biotech companies, today announced results from a six-month deployment at Stanford Health Care of MyVisionTrack (mVT), a vision monitoring app that allows patients with macular diseases to test their vision on a mobile device between clinical visits and send real-time updates to their care team. Developed on BrightInsight's platform and registered with the FDA as a Software as a Medical Device (SaMD), mVT was prescribed to patients living with retinal conditions including wet AMD (nAMD), intermediate AMD (iAMD), and diabetic macular edema (DME). Full findings will be presented at ARVO in May 2026.
Under the leadership of Theodore Leng, MD, MS, FACS, Professor of Ophthalmology at Stanford University School of Medicine, the program tracked adherence, retention, and clinical utility across six months of real-world use — and challenged one of the most persistent assumptions in digital health: that older patients won’t engage.
For the millions of patients managing retinal disease, the space between clinic visits has often been a challenge. Vision can change quickly, and traditional care has no mechanism to catch changes before the next scheduled appointment. By then, the window for early intervention may have passed.
"The mVT data gave us something we’ve never had before in retinal care — a real-time window into how patients are doing between visits. The alerts were clinically meaningful, the patients felt reassured, and the workflow integrated seamlessly into our practice." — Theodore Leng, MD, MS, FACS, Professor of Ophthalmology, Stanford University School of Medicine
Patients Who Start, Stay
Of 66 patients who received mVT prescriptions, 48 successfully completed the full registration journey — and among those, 83% remained active at the close of the observation period (defined as completing at least one test in the final 30 days), suggesting the program will exceed its annual retention target of 30%.
The data points to a clear conversion threshold: registration plus a first test. Patients who cleared both steps were far more likely to stay engaged going forward. The drop-off is concentrated before that threshold, not after it. The data suggests inertia, not dissatisfaction, drives early discontinuation.
Debunking the Age Barrier
Most registered patients established a reliable testing baseline within their first two weeks of use. The median age of those patients was 76 with the largest single cohort, 27% of users, in the 76–80 age bracket. The population retinal disease most commonly affects, it turns out, is also one that will pick up a smartphone and test their own vision twice a week.
The data also revealed a mechanism for further strengthening engagement. App-based reminders drove measurable behavior change, as patients who set them tested their vision 20% more frequently than those who didn't. And among reminder users, three in four set alerts for five or more days per week. The signal is clear: structured prompting builds consistent testing habits without adding clinical staff burden.
"This program validates what we’ve seen across our broader platform: when patients are given the right tool and appropriate onboarding, they engage — and stay engaged. Age is not the barrier the industry assumes it is. What determines whether patients stay is whether the experience holds long after the prescription is written." — Kal Patel, MD, CEO and Co-Founder, BrightInsight
During the six-month program, mVT triggered three clinically significant alerts — capturing both vision improvement and vision deterioration events — enabling the Stanford team to intervene proactively rather than wait for the next scheduled visit. The clinical team described the alert workflow as efficient and well-integrated into practice. Patients on the receiving end shared that knowing their physician was actively monitoring their vision between appointments made them feel reassured rather than alone.
Coming to ARVO 2026
Dr. Leng will present the full mVT dataset and clinical findings at ARVO (Association for Research in Vision and Ophthalmology) in May 2026. Media representatives interested in speaking with Dr. Leng ahead of his ARVO presentation may contact Nicole Warshauer at nicole.warshauer@brightinsight.com to request a briefing.
About BrightInsight
BrightInsight is the patient persistence solution for the world's top pharma and biotech companies. BrightInsight helps patients start — and stay on — life-changing therapy by detecting the behavioral signals that precede drop-off and intervening before discontinuation becomes a decision. Built to scale globally with the compliance infrastructure that regulated markets demand, BrightInsight is the foundation global biopharma brands rely on to realize the full value of their therapies. For more details, visit BrightInsight’s website, Blog, and LinkedIn pages.
Media Contact
Nicole Warshauer
VP of Marketing, BrightInsight
nicole.warshauer@brightinsight.com